Liver Metastases clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
Sorry, in progress, not accepting new patients
The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.
San Francisco, California and other locations
Our lead scientists for Liver Metastases research studies include Nicholas Fidelman.